Bladder cancer Pt with rare genetic mutations shows exceptional response to ... EurekAlert (press release) PHILADELPHIA — A patient with advanced bladder cancer experienced a complete response for 14 months to the drug combination everolimus and pazopanib in a phase I trial, and genomic profiling of his tumor revealed two alterations that may have ... |
